Literature DB >> 8949567

Long-term follow-up of patients with hyperprolactinaemia.

W J Jeffcoate1, N Pound, N D Sturrock, J Lambourne.   

Abstract

AIM: To determine the frequency with which hyperprolactinaemic illness tends to resolve with time. STUDY
DESIGN: A retrospective case-notes review from a specialist endocrine unit in a provincial teaching hospital and tertiary referral centre. PATIENTS: Seventy women with hyperprolactinaemia referred to the unit in the 15 year period between May 1979 and May 1994. All those with a non-pituitary cause or with macroadenoma had been excluded, as were those who did not have high-resolution imaging, or who were on treatment at the time of referral. INTERVENTION: Intermittent course of treatment with dopamine receptor agonists according to individual need. ENDPOINTS: Latest serum PRL concentration in those who had discontinued treatment, and whether serum PRL tended to be lower in any particular group.
RESULTS: There was a significant fall in median PRL concentration from 2000 (714-8000) to 1000 mU/l (220-5600) in the 31 women who had discontinued therapy (P < 0.0005), and serum PRL was normal (< 700 mU/l) in 11 of them. Serum PRL also fell to normal in three of ten women who had no treatment at all. Final PRL concentration was normal in 35% of women who had had at least one pregnancy during the period of follow-up compared to 14% who had not (P < 0.05).
CONCLUSIONS: These data confirm the findings of others that hyperprolactinaemia will prove self-limiting in up to one-third of women, and that pregnancy may be one factor which triggers a return to normal function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8949567     DOI: 10.1046/j.1365-2265.1996.00824.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

Review 1.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 3.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 4.  Do nothing but observe microprolactinomas: when and how to replace sex hormones?

Authors:  Vivien Bonert
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

5.  Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.

Authors:  Margarida Teixeira; Pedro Souteiro; Davide Carvalho
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 6.  Prolactinomas and menopause: any changes in management?

Authors:  Yona Greenman
Journal:  Pituitary       Date:  2020-02       Impact factor: 4.107

Review 7.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

8.  Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.

Authors:  P Touraine; C Deneux; G Plu-Bureau; P Mauvais-Jarvis; F Kuttenn
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

Review 9.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

10.  Macroprolactinemia: the consequences of a laboratory pitfall.

Authors:  Erzsébet Toldy; Zoltán Löcsei; István Szabolcs; Miklós I Góth; Pál Kneffel; Dominika Szöke; Gábor L Kovács
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.